$2.85
0.020.71%
Pre-Market: Jul 19, 7:55 PM EDT
15 minutes delayed
Comments
Loading...
Allogene Therapeutics
ALLONASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Allogene Therapeutics (NASDAQ:ALLO) Stock, Analyst Ratings, Price Targets, Forecasts
Allogene Therapeutics Inc has a consensus price target of $14.92 based on the ratings of 20 analysts. The high is $35 issued by Canaccord Genuity on June 16, 2023. The low is $4.6 issued by Stifel on May 14, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Oppenheimer, and HC Wainwright & Co. on May 31, 2024, May 21, 2024, and May 16, 2024, respectively. With an average price target of $11 between Piper Sandler, Oppenheimer, and HC Wainwright & Co., there's an implied 285.96% upside for Allogene Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Oppenheimer
HC Wainwright & Co.
Truist Securities
Stifel
1calculated from analyst ratings
Analyst Ratings for Allogene Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 285.96% | Piper Sandler | Biren Amin | → $11 | Initiates | → Overweight | Get Alert |
| 05/21/2024 | Buy Now | 356.14% | Oppenheimer | Mark Breidenbach | $14 → $13 | Maintains | Outperform | Get Alert |
| 05/16/2024 | Buy Now | 215.79% | HC Wainwright & Co. | Robert Burns | $10 → $9 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | 496.49% | Truist Securities | Asthika Goonewardene | → $17 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 61.4% | Stifel | Benjamin Burnett | $4.4 → $4.6 | Maintains | Hold | Get Alert |
| 03/19/2024 | Buy Now | 250.88% | HC Wainwright & Co. | Robert Burns | → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 250.88% | RBC Capital | Luca Issi | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 180.7% | JP Morgan | Brian Cheng | $9 → $8 | Maintains | Overweight | Get Alert |
| 01/19/2024 | Buy Now | 250.88% | HC Wainwright & Co. | Robert Burns | $12 → $10 | Maintains | Buy | Get Alert |
| 01/05/2024 | Buy Now | — | Guggenheim | Michael Schmidt | — | Downgrade | Buy → Neutral | Get Alert |
| 01/05/2024 | Buy Now | — | JMP Securities | Reni Benjamin | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 12/08/2023 | Buy Now | 145.61% | Citigroup | Samantha Semenkow | → $7 | Initiates | → Buy | Get Alert |
| 11/15/2023 | Buy Now | 321.05% | HC Wainwright & Co. | Robert Burns | $23 → $12 | Maintains | Buy | Get Alert |
| 09/25/2023 | Buy Now | 215.79% | JP Morgan | Brian Cheng | $11 → $9 | Maintains | Overweight | Get Alert |
| 08/07/2023 | Buy Now | 707.02% | HC Wainwright & Co. | Robert Burns | → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 426.32% | EF Hutton | Tony Butler | → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 882.46% | Oppenheimer | Mark Breidenbach | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 07/12/2023 | Buy Now | 531.58% | Truist Securities | Asthika Goonewardene | $20 → $18 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 882.46% | Oppenheimer | Mark Breidenbach | → $28 | Assumes | → Outperform | Get Alert |
| 06/20/2023 | Buy Now | 707.02% | HC Wainwright & Co. | Robert Burns | → $23 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 1128.07% | Canaccord Genuity | John Newman | → $35 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 426.32% | EF Hutton | Tony Butler | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 426.32% | JMP Securities | Reni Benjamin | → $15 | Reiterates | → Market Outperform | Get Alert |
| 05/26/2023 | Buy Now | 426.32% | EF Hutton | Tony Butler | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 426.32% | JMP Securities | Reni Benjamin | $19 → $15 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 707.02% | HC Wainwright & Co. | Robert Burns | → $23 | Reiterates | → Buy | Get Alert |
| 05/04/2023 | Buy Now | 163.16% | Stifel | Benjamin Burnett | $8 → $7.5 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | 426.32% | RBC Capital | Luca Issi | → $15 | Reiterates | → Outperform | Get Alert |
| 04/20/2023 | Buy Now | 707.02% | HC Wainwright & Co. | Robert Burns | → $23 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 566.67% | JMP Securities | Reni Benjamin | → $19 | Reiterates | → Market Outperform | Get Alert |
| 04/17/2023 | Buy Now | 426.32% | EF Hutton | Tony Butler | → $15 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | 707.02% | HC Wainwright & Co. | Robert Burns | $29 → $23 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 110.53% | Bernstein | William Pickering | → $6 | Initiates | → Market Perform | Get Alert |
| 03/02/2023 | Buy Now | 987.72% | Goldman Sachs | Salveen Richter | $35 → $31 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 566.67% | JMP Securities | Benjamin Chaiken | $23 → $19 | Maintains | Market Perform | Get Alert |
| 03/01/2023 | Buy Now | 426.32% | EF Hutton | Tony Butler | → $15 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 671.93% | RBC Capital | Luca Issi | $32 → $22 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 882.46% | Oppenheimer | Mark Breidenbach | $32 → $28 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 987.72% | Goldman Sachs | Salveen Richter | $35 → $31 | Maintains | Buy | Get Alert |
| 01/24/2023 | Buy Now | 285.96% | JP Morgan | Brian Cheng | $20 → $11 | Upgrade | Neutral → Overweight | Get Alert |
| 01/06/2023 | Buy Now | 321.05% | Baird | Jack Allen | → $12 | Upgrade | Neutral → Outperform | Get Alert |
| 01/05/2023 | Buy Now | 426.32% | EF Hutton | Tony Butler | → $15 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | 215.79% | B of A Securities | Jason Gerberry | → $9 | Downgrade | Buy → Underperform | Get Alert |
| 11/21/2022 | Buy Now | 917.54% | HC Wainwright & Co. | Debjit Chattopadhyay | $43 → $29 | Maintains | Buy | Get Alert |
| 09/22/2022 | Buy Now | 531.58% | B. Riley Securities | Kalpit Patel | $21 → $18 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 1128.07% | Oppenheimer | Mark Breidenbach | $40 → $35 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 1022.81% | RBC Capital | Luca Issi | $35 → $32 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | — | Raymond James | Dane Leone | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/15/2022 | Buy Now | 1022.81% | Goldman Sachs | Salveen Richter | $9 → $32 | Upgrade | Neutral → Buy | Get Alert |
| 06/03/2022 | Buy Now | 285.96% | Baird | Jack Allen | → $11 | Initiates | → Neutral | Get Alert |
| 05/24/2022 | Buy Now | 215.79% | Goldman Sachs | Salveen Richter | $12 → $9 | Maintains | Neutral | Get Alert |
| 05/05/2022 | Buy Now | 356.14% | Raymond James | Dane Leone | $36 → $13 | Maintains | Outperform | Get Alert |
| 03/07/2022 | Buy Now | 321.05% | Goldman Sachs | Salveen Richter | $20 → $12 | Maintains | Neutral | Get Alert |
| 12/14/2021 | Buy Now | 1128.07% | RBC Capital | Luca Issi | — | Maintains | Outperform | Get Alert |
| 10/12/2021 | Buy Now | 847.37% | JMP Securities | Reni Benjamin | — | Maintains | Market Outperform | Get Alert |
| 10/08/2021 | Buy Now | — | Stifel | Benjamin Burnett | — | Downgrade | Buy → Hold | Get Alert |
| 10/08/2021 | Buy Now | 1478.95% | RBC Capital | Luca Issi | — | Maintains | Outperform | Get Alert |
| 10/08/2021 | Buy Now | 601.75% | Goldman Sachs | Salveen Richter | — | Downgrade | Buy → Neutral | Get Alert |
| 09/24/2021 | Buy Now | 1163.16% | Raymond James | Dane Leone | — | Upgrade | Market Perform → Outperform | Get Alert |
| 09/23/2021 | Buy Now | 1163.16% | Raymond James | Dane Leone | — | Upgrade | Market Perform → Outperform | Get Alert |
FAQ
What is the target price for Allogene Therapeutics (ALLO) stock?
The latest price target for Allogene Therapeutics (NASDAQ:ALLO) was reported by Piper Sandler on May 31, 2024. The analyst firm set a price target for $11.00 expecting ALLO to rise to within 12 months (a possible 285.96% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Allogene Therapeutics (ALLO)?
The latest analyst rating for Allogene Therapeutics (NASDAQ:ALLO) was provided by Piper Sandler, and Allogene Therapeutics initiated their overweight rating.
When was the last upgrade for Allogene Therapeutics (ALLO)?
The last upgrade for Allogene Therapeutics Inc happened on January 24, 2023 when JP Morgan raised their price target to $11. JP Morgan previously had a neutral for Allogene Therapeutics Inc.
When was the last downgrade for Allogene Therapeutics (ALLO)?
The last downgrade for Allogene Therapeutics Inc happened on January 5, 2024 when Guggenheim changed their price target from N/A to N/A for Allogene Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Allogene Therapeutics (ALLO) correct?
While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a initiated with a price target of $0.00 to $11.00. The current price Allogene Therapeutics (ALLO) is trading at is $2.85, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.